Stephen F. Betz - 31 Mar 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
31 Mar 2022
Net transactions value
-$178,475
Form type
4
Filing time
01 Apr 2022, 17:39:05 UTC
Previous filing
17 Mar 2022
Next filing
06 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale $87,700 -4,164 -3.1% $21.06 129,673 31 Mar 2022 Direct F1, F2
transaction CRNX Common Stock Sale $90,775 -4,164 -3.2% $21.80 125,509 01 Apr 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.0614 per share. The range of sales prices on the transaction date was $21.0201 to $21.0774 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.